Research & Development

R&D

R&D Pipline

5 anti-diabetic drugs & 1 obesity drug

Long-acting, injectable products based on ExtennaTM microsphere technology

Drug Competitor AULBIO Status Indication Drug type
AUL001 Weekly Monthly Formulation Complete
/Animal Study under Discussion
Diabetes Peptide
(Synthesis)
AUL002 Daily Monthly Formulation in Development Diabetes Peptide
(Recombinant DNA)
AUL003 Daily Monthly Formulation in Development
/Bioassay
Diabetes Protein
(Recombinant DNA)
AUL004 Daily Monthly Formulation in Development Diabetes Peptide
(Synthesis)
AUL005 Weekly Monthly Formulation in Development Diabetes Peptide
(Synthesis/fusion)
AUL006 Daily Monthly Formulation in Development Obesity Peptide
(Recombinant DNA)